CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis Pharmaceuticals Corporation v. Ranbaxy Inc.

1:14-cv-01526

Overview

Case Number 1:14-cv-01526
Filing Date 2014-12-29
Status Terminated
Termination Date 2015-10-21
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Ranbaxy Inc. Operating Company

Represented By

5 Attorneys Listed

Frederick L. Cottrell , III

Richards, Layton & Finger, PA

Tel: +1 (302) 658-6541

Richards, Layton & Finger, PA, One Rodney Square

William R. Zimmerman

Email: bill.zimmerman@knobbe.com

Jonathan E. Bachand

Email: jonathan.bachand@knobbe.com

Arun John Mohan

Schiff Hardin LLP

Tel: +1 (212) 745-9536
Fax: +1 (212) 753-5044

666 Fifth Avenue, Suite 1700, New York, NY 10103

Loni L. Morrow

Email: loni.morrow@knobbe.com

Sun Pharmaceutical Industries Ltd. Operating Company

Represented By

2 Attorneys Listed

Frederick L. Cottrell , III

Richards, Layton & Finger, PA

Tel: +1 (302) 658-6541

Richards, Layton & Finger, PA, One Rodney Square

Arun John Mohan

Schiff Hardin LLP

Tel: +1 (212) 745-9536
Fax: +1 (212) 753-5044

666 Fifth Avenue, Suite 1700, New York, NY 10103

Novartis AG Operating Company

Represented By

3 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis Pharmaceuticals Corporation Operating Company

Represented By

3 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Counter Claimant

Ranbaxy Laboratories Ltd. Operating Company

Represented By

2 Attorneys Listed

Frederick L. Cottrell , III

Richards, Layton & Finger, PA

Tel: +1 (302) 658-6541

Richards, Layton & Finger, PA, One Rodney Square

Arun John Mohan

Schiff Hardin LLP

Tel: +1 (212) 745-9536
Fax: +1 (212) 753-5044

666 Fifth Avenue, Suite 1700, New York, NY 10103

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 6 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (6): 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6894051
Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Filed: 1998-07-16
Issued: 2005-05-17
Expired (Term Ended) +311d PTA
Expires: 2019-05-23
USRE43932
Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Filed: 2011-09-21
Issued: 2013-01-15
Active (4.8 yrs remaining)
Expires: 2031-09-21

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+311 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

4

Dispositive

0

Granted

0

Denied

0

Pending / Review

4

Motions by Category

Procedural / Extension Motion 4

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to submit a Proposed Scheduling Order to Friday, October 30, 2015 (from Monday, August 31, 2015) - filed by Novartis AG, Novartis Pha...
Entry #21 • 2015-08-26 Document →
Procedural / Extension Motion Pending / Under Review
Third STIPULATION TO EXTEND TIME to answer and file any counterclaims in response to the Complaint to and including May 29, 2015 - filed by Ranbaxy Inc., Ranbax...
Entry #12 • 2015-04-30 Document →
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for Defendants to answer and file any counterclaims in response to the Complaint to April 30, 2015 - filed by Ranbaxy Inc., Ranbaxy L...
Entry #10 • 2015-03-24 Document →
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to answer and file any counterclaims to and including March 30, 2015 - filed by Ranbaxy Inc., Ranbaxy Laboratories Ltd.. (Cottrell, F...
Entry #9 • 2015-02-23 Document →

Docket Entries

(36 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Ranbaxy Inc., Ranbaxy Laboratories Ltd. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1647068.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet, # 4 Civil Cover Sheet Attachment)(dmp, ) Modified on 12/30/2014 (dmp, ). (Entered: 12/30/2014)

Entry #1 • 2014-12-29
1
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Ranbaxy Inc., Ranbaxy Laboratories Ltd. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1647068.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet, # 4 Civil Cover Sheet Attachment)(dmp, ) Modified on 12/30/2014 (dmp, ). (Entered: 12/30/2014)

Entry #1 • 2014-12-29
2
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Ranbaxy Inc., Ranbaxy Laboratories Ltd. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1647068.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet, # 4 Civil Cover Sheet Attachment)(dmp, ) Modified on 12/30/2014 (dmp, ). (Entered: 12/30/2014)

Entry #1 • 2014-12-29
2
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Ranbaxy Inc., Ranbaxy Laboratories Ltd. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1647068.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet, # 4 Civil Cover Sheet Attachment)(dmp, ) Modified on 12/30/2014 (dmp, ). (Entered: 12/30/2014)

Entry #1 • 2014-12-29
2
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Ranbaxy Inc., Ranbaxy Laboratories Ltd. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1647068.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet, # 4 Civil Cover Sheet Attachment)(dmp, ) Modified on 12/30/2014 (dmp, ). (Entered: 12/30/2014)

Entry #1 • 2014-12-29
2

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc